The ABPI welcomes the announcement that the Medical Research Council and the Technology Strategy Board are committing almost £26 million to enable innovative life science projects through the third round of the Biomedical Catalyst.
This is a welcome boost to small and medium sized enterprises which will enable them to take forward discoveries with proof of concept, including stratified medicines, to the next stage of development. Furthermore the announcement of the new National Biologics Manufacturing Centre in Darlington is another welcome development. It will provide a significant new UK resource for the manufacture of biological medicines. The ABPI will offer its full support to the new centre.
ABPI Press OfficeTel: +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641811 Email: email@example.com
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.